Two major clinical studies, including a global phase 3 trial and the ATTAIN-2 study, offer the strongest picture of how the pill performs
Novo Nordisk is also investigating a triple agonist of GLP-1, GIP, and glucagon receptors
About this article Cite this article Wen, H., Zhao, K., Luo, X
Research shows that 300 mg daily oral glutathione for four months significantly reduced liver inflammation markers in patients with nonalcoholic fatty liver disease
Contact your GP if tiredness persists beyond 46 weeks, significantly impairs daily activities, is accompanied by frequent hypoglycaemia, signs of dehydration, unexplained weight loss, mood changes, or symptoms suggesting sleep apnoea such as excessive daytime sleepiness